Literature DB >> 11268452

Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.

J T Hartmann1, L M Fels, A Franzke, S Knop, M Renn, B Maess, P Panagiotou, H Lampe, L Kanz, H Stolte, C Bokemeyer.   

Abstract

The nephrotoxic effects of different platinum compounds based combination chemotherapies were compared. Chemotherapy consisted of either cisplatin fractionated over 5 days (5 x 20 mg/m2) or given as a single-day infusion (1 x 50 mg/m2) plus ifosfamide (4 g/m2) or high-dose chemotherapy was applied including carboplatin (3 x 500 mg/m2) and ifosfamide (3 x 4 g/m2) fractionated over three consecutive days. Conventional parameters such as serum creatinine and glomerular filtration rate (GFR), as well as urinary protein excretion of N-acetyl-beta-D-glucosaminidase (NAG)) and alpha 1-micro-globulin were assessed in 52 patients. Fractionation over 5 days without adding other nephrotoxic agents, i.e. ifosfamide, prevented decreases in GFR following cisplatin, whereas the combination of conventional dose cisplatin and ifosfamide, given as a single-day infusion, and high-dose carboplatin/ifosfamide yielded a pronounced fall of GFR. All groups showed increases in the urinary excretion levels of serum derived proteins and NAG, but with significant differences; about 2 to 3-fold for 5-days cisplatin, 3 to 5-fold for single-day cisplatin/ifosfamide, and 20 to 35-fold for high-dose chemotherapy. Thus, conventional approaches can reduce but not prevent the nephrotoxicity of cisplatin-based chemotherapy. In particular, high-dose chemotherapy regimens including carboplatin and ifosfamide are associated with comparable or even higher nephrotoxicity to single-day cisplatin/ifosfamide. In the light of the long-term consequences of persistent renal damage prevention of nephrotoxicity should be further improved.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11268452

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group.

Authors:  Deborah P Jones; Sheri L Spunt; Daniel Green; James E Springate
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

2.  Long-term nephrotoxicity in adult survivors of childhood cancer.

Authors:  Ilona A Dekkers; Karin Blijdorp; Karlien Cransberg; Saskia M Pluijm; Rob Pieters; Sebastian J Neggers; Marry M van den Heuvel-Eibrink
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 8.237

Review 3.  [Nutrition, lifestyle, physical activity, and supportive care during chemotherapeutic treatment].

Authors:  G Lümmen; T Jäger; F Sommer; T Ebert; B Schmitz-Draeger
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

4.  Nephroprotective effect of Apium graveolens L. against Cisplatin-induced nephrotoxicity.

Authors:  Mohd Naushad; Mohd Urooj; Tasleem Ahmad; Gulam Mohammed Husain; Munawwar Husain Kazmi; Mohammad Zakir
Journal:  J Ayurveda Integr Med       Date:  2021-11-11

5.  A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.

Authors:  J T Hartmann; A von Vangerow; L M Fels; S Knop; H Stolte; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

Review 6.  Prevention of Chemotherapy-Induced Nephrotoxicity in Children with Cancer.

Authors:  Fatemeh Ghane Sharbaf; Hamid Farhangi; Farahnak Assadi
Journal:  Int J Prev Med       Date:  2017-10-05

7.  Myalgia and Hematuria in Association with Clonidine and Arginine Administration for Growth Hormone Stimulation Tests.

Authors:  Meghan Glibbery; Adam Fleming; Rahul Chanchlani; Olufemi Abiodun Ajani; Norma Marchetti; Alexa Marr; M Constantine Samaan
Journal:  Case Rep Med       Date:  2020-05-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.